Literature DB >> 10051290

Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages.

X P Xu1, S R Meisel, J M Ong, S Kaul, B Cercek, T B Rajavashisth, B Sharifi, P K Shah.   

Abstract

BACKGROUND: Macrophages in human atherosclerotic plaques produce a family of matrix metalloproteinases (MMPs), which may influence vascular remodeling and plaque disruption. Because oxidized LDL (ox-LDL) is implicated in many proatherogenic events, we hypothesized that ox-LDL would regulate expression of MMP-9 and tissue inhibitor of metalloproteinase-1 (TIMP-1) in monocyte-derived macrophages. MWRHOSA AND
RESULTS: Mononuclear cells were isolated from normal human subjects with Ficoll-Paque density gradient centrifugation, and adherent cells were allowed to differentiate into macrophages during 7 days of culture in plastic dishes. On day 7, by use of serum-free medium, the macrophages were incubated with various concentrations of native LDL (n-LDL) and copper-oxidized LDL. Exposure to ox-LDL (10 to 50 microg/mL) increased MMP-9 mRNA expression as analyzed by Northern blot, protein expression as measured by ELISA and Western blot, and gelatinolytic activity as determined by zymography. The increase in MMP-9 expression was associated with increased nuclear binding of transcription factor NF-kappaB and AP-1 complex on electromobility shift assay. In contrast, ox-LDL (10 to 50 microg/mL) decreased TIMP-1 expression. Ox-LDL-induced increase in MMP-9 expression was abrogated by HDL (100 microg/mL). n-LDL had no significant effect on MMP-9 or TIMP-1 expression.
CONCLUSIONS: These data demonstrate that unlike n-LDL, ox-LDL upregulates MMP-9 expression while reducing TIMP-1 expression in monocyte-derived macrophages. Furthermore, HDL abrogates ox-LDL-induced MMP-9 expression. Thus, ox-LDL may contribute to macrophage-mediated matrix breakdown in the atherosclerotic plaques, thereby predisposing them to plaque disruption and/or vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051290     DOI: 10.1161/01.cir.99.8.993

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  35 in total

Review 1.  Clinical implications of matrix metalloproteinases.

Authors:  Malay Mandal; Amritlal Mandal; Sudip Das; Tapati Chakraborti; Chakraborti Sajal
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

Review 2.  [Non-lipid effects of statins: myth or fact?].

Authors:  Eleonora Urbauer; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2003

3.  Influence of oxidatively modified LDL on monocyte-macrophage differentiation.

Authors:  Achuthan Radhika; Shiney S Jacob; Perumana R Sudhakaran
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

4.  Effects of increasing docosahexaenoic acid intake in human healthy volunteers on lymphocyte activation and monocyte apoptosis.

Authors:  Saïda Mebarek; Natalia Ermak; Amal Benzaria; Stéphanie Vicca; Madeleine Dubois; Georges Némoz; Martine Laville; Bernard Lacour; Evelyne Véricel; Michel Lagarde; Annie-France Prigent
Journal:  Br J Nutr       Date:  2008-08-19       Impact factor: 3.718

Review 5.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

6.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

Review 7.  Matrix metalloproteinases, atherosclerosis, proteinuria and kidney disease: Linkage-based approaches.

Authors:  G Dimas; F Iliadis; D Grekas
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

Review 8.  Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges.

Authors:  Shuaibo Huang; Nikolaos G Frangogiannis
Journal:  Br J Pharmacol       Date:  2018-03-04       Impact factor: 8.739

9.  Regulations of the key mediators in inflammation and atherosclerosis by aspirin in human macrophages.

Authors:  Li Lu; Hong Liu; Jiahe Peng; Lin Gan; Lili Shen; Qian Zhang; Liangpeng Li; Li Zhang; Chang Su; Yu Jiang
Journal:  Lipids Health Dis       Date:  2010-02-06       Impact factor: 3.876

Review 10.  Ceramide: a common pathway for atherosclerosis?

Authors:  Jean Bismuth; Peter Lin; Qizhi Yao; Changyi Chen
Journal:  Atherosclerosis       Date:  2007-10-25       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.